Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic collaborations, and regulatory milestones.
Access curated press releases and news articles covering Curis’s pipeline developments, including its lead candidate emavusertib, partnership updates with Aurigene and Genentech, and financial performance. The resource is designed to help users track progress across hematologic and solid tumor indications while staying informed about licensing agreements and scientific advancements.
Content spans clinical trial results, FDA designations, earnings reports, and research publications. Bookmark this page for direct access to verified updates on Curis’s innovative approaches to modulating cancer pathways and expanding treatment options.
Curis, Inc. (NASDAQ: CRIS) announced the publication of a manuscript in Gastroenterology, detailing the role of IRAK4 in pancreatic ductal adenocarcinoma (PDAC) and the preclinical efficacy of the IRAK4 inhibitor emavusertib (CA-4948) combined with checkpoint immunotherapy. The study indicates that targeting IRAK4 could counteract tumor-induced T-cell exhaustion and improve responses to treatment. The research suggests potential broader applications of emavusertib in solid tumors, highlighting its promise in addressing significant unmet patient needs in cancer therapeutics.
Curis, Inc. (NASDAQ: CRIS) reported its Q4 2021 financial results, showing a net loss of $13.6 million or $0.15 per share, compared to a net loss of $7.5 million in Q4 2020. Total revenues for 2021 were $10.6 million, slightly down from $10.8 million in 2020. Notably, Curis announced promising clinical progress in its pipeline, particularly for emavusertib (CA-4948) in leukemia treatment, and favorable safety data for CI-8993. The company plans to discuss a rapid FDA registration path and continues to see operational growth with new executive appointments.
Curis, Inc. (NASDAQ: CRIS) will release its Q4 2021 financial results on February 24, 2022, after U.S. markets close. Management will host a conference call at 4:30 PM ET on the same day. Investors can join the call by dialing (888) 346-6389 (U.S.) or (412) 317-5252 (international). The call will also be available on Curis's website. The company specializes in cancer therapeutics, and its pipeline includes the IRAK4 kinase inhibitor CA-4948, currently in clinical trials for various hematologic malignancies.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will participate in two upcoming conferences: the B. Riley Virtual Oncology Conference on January 27, 2022, at 1:30 p.m. ET, and the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 11:20 a.m. ET. Live webcasts of these presentations will be accessible on their website, and archived replays will be available for 90 days afterward.
Curis focuses on innovative cancer therapeutics, including trials on the IRAK4 inhibitor CA-4948.
Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options on January 3, 2022, granting 224,700 shares to eleven new employees. The options have a 10-year term, with vesting over four years based on continued employment. Each grant's exercise price matches the stock's closing price on the grant date, incentivizing new hires as part of the company's growth strategy in cancer therapeutics. Curis focuses on innovating treatments, particularly in immuno-oncology, with several clinical trials underway for its drug candidates.
Curis, Inc. (NASDAQ: CRIS) announced positive clinical data from its ongoing Phase 1/2 study of CA-4948, an IRAK-4 inhibitor, for treating relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). As of December 16, 2021, CA-4948 was well-tolerated, with no dose-limiting toxicities reported, and showed promising anti-cancer activity with a 40% complete response rate in AML patients with specific mutations. Curis also reported initial positive safety data for CI-8993, a monoclonal antibody targeting VISTA, currently in Phase 1 trials for solid tumors.
Curis, Inc. (NASDAQ: CRIS) announced the appointment of three new executives to enhance its management team as of January 3, 2022. Felix Geissler, M.D., Ph.D., becomes Vice President of Medical Affairs; Kimberly Steinmann, M.D., Vice President of Clinical Development; and Dora Ferrari, Vice President of Clinical Operations. These appointments aim to bolster internal capabilities for advancing clinical drug candidates CA-4948 and CI-8993. The company is focused on developing innovative cancer therapeutics and has collaborations for its drug candidates, including ongoing trials.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, starting at 7:00 a.m. ET. The presentation will be available for on-demand viewing afterward. A live webcast can be viewed in the Investors section of Curis' website and will remain accessible for 90 days. Curis focuses on developing cancer therapeutics, including collaborations on various oncology treatments, such as the IRAK4 inhibitor CA-4948, currently in trials for non-Hodgkin lymphoma and acute myeloid leukemia.
Curis, Inc. (NASDAQ: CRIS) has been added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF, effective before market open on December 20, 2021. Curis focuses on innovative cancer therapeutics, with ongoing clinical trials for several drug candidates, including CA-4948, which has received Orphan Drug Designation for acute myeloid leukemia. The company collaborates with Aurigene and ImmuNext, and their partnership with Genentech commercializes Erivedge for advanced basal cell carcinoma.
Curis, Inc. (NASDAQ: CRIS) announced the appointment of John A. Hohneker, M.D., to its Board of Directors on Dec. 6, 2021. Dr. Hohneker brings over 30 years of biopharmaceutical experience, previously serving as President and CEO of Anokion SA and in leadership roles at Novartis. His expertise will support Curis in accelerating drug candidates, particularly the first-in-class IRAK4 inhibitor, CA-4948, currently in clinical trials for various cancers. This appointment is seen as pivotal for Curis's future growth and potential commercialization of its therapies.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
